Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AYTU 
Aytu BioScience Inc (AYTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: AYTU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.17
1 Year Target Price $9.17
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.56% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.19M USD | Price to earnings Ratio - | 1Y Target Price 9.17 |
Price to earnings Ratio - | 1Y Target Price 9.17 | ||
Volume (30-day avg) 1 | Beta 0.28 | 52 Weeks Range 0.95 - 2.82 | Updated Date 10/14/2025 |
52 Weeks Range 0.95 - 2.82 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-09-23 | When - | Estimate 0.53 | Actual -2.93 |
Profitability
Profit Margin -20.43% | Operating Margin (TTM) 4.23% |
Management Effectiveness
Return on Assets (TTM) 1.31% | Return on Equity (TTM) -60.76% |
Valuation
Trailing PE - | Forward PE 3.69 | Enterprise Value 10389468 | Price to Sales(TTM) 0.35 |
Enterprise Value 10389468 | Price to Sales(TTM) 0.35 | ||
Enterprise Value to Revenue 0.16 | Enterprise Value to EBITDA 1.14 | Shares Outstanding 9911913 | Shares Floating 6457810 |
Shares Outstanding 9911913 | Shares Floating 6457810 | ||
Percent Insiders 9.34 | Percent Institutions 34.49 |
Upturn AI SWOT
Aytu BioScience Inc
Company Overview
History and Background
Aytu BioScience, Inc. (formerly Aytu Pharma, Inc.) was founded in 2015 and has evolved through acquisitions and strategic realignments, focusing on commercializing products addressing significant patient needs. The company has undergone several name and strategy changes.
Core Business Areas
- Rx Portfolio (Commercial): Focused on commercializing prescription products, including Natesto for low testosterone and ZolpiMist for insomnia.
- Consumer Health: Markets consumer health products through various channels, including dietary supplements.
Leadership and Structure
Details regarding current leadership and organizational structure are needed. Current information is difficult to acquire as the company is no longer publically traded.
Top Products and Market Share
Key Offerings
- Natesto: A nasal gel for treating hypogonadism (low testosterone) in men. Historical market share data is unavailable but competed with other testosterone replacement therapies. Key competitors included AbbVie (AndroGel), Eli Lilly (Axiron).
- ZolpiMist: An oral spray formulation of zolpidem for treating insomnia. Historical market share data is unavailable but competed with other insomnia treatments like Ambien (Sanofi) and Lunesta (Sunovion).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and evolving market dynamics. The market for testosterone replacement therapy and insomnia treatments is significant.
Positioning
AYTU (prior to ceasing to be publically traded) sought to carve a niche by focusing on specific formulations and delivery methods. Its smaller size posed a challenge against larger, established pharmaceutical companies.
Total Addressable Market (TAM)
TAM for testosterone replacement therapy and insomnia treatments is in the billions of dollars. AYTU's positioning was relative to its ability to capture market share within these large markets. Data would be needed to quantify.
Upturn SWOT Analysis
Strengths
- Established products with clinical data
- Potential for growth in niche markets
- Experienced management team (historic)
Weaknesses
- Limited financial resources
- Small market share compared to major competitors
- Dependence on key products
Opportunities
- Expansion into new markets
- Acquisition of complementary products
- Strategic partnerships
Threats
- Competition from larger pharmaceutical companies
- Generic versions of key products
- Regulatory changes
Competitors and Market Share
Key Competitors
- ABBV
- SNY
- LLY
Competitive Landscape
AYTU was a smaller player competing with larger, established pharmaceutical companies. AYTU advantages and disadvantages are related to competitors.
Growth Trajectory and Initiatives
Historical Growth: Requires historical financial data to assess growth trends.
Future Projections: Future projections were not available when the company stopped trading publically. Analysis estimates were based on analyst reports.
Recent Initiatives: Requires data about recent strategic initiatives. Company delisted and its direction is unknown.
Summary
Aytu BioScience, before ceasing to be publically traded, was a smaller pharmaceutical company focused on niche markets like testosterone replacement and insomnia treatments. They faced challenges competing with larger companies and had limited financial resources. To strengthen, they would have needed to expand their product portfolio and secure strategic partnerships. A key threat remained competition from established players and potential generic entry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Public Filings (historical)
- Company Press Releases (historical)
- Analyst Reports (historical)
- SEC Filings
Disclaimers:
This analysis is based on historical data and information available prior to the companyu2019s delisting. Current and future performance may differ significantly. Market share and financial data are estimates based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | CEO & Director Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 82 | Website https://aytubio.com |
Full time employees 82 | Website https://aytubio.com | ||
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.